Skip to main content

Table 3 Potential risk factors for the first major infection in 103 patients with SLE

From: Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus

 

= 1 major infection (n = 23)

No major infection (n = 80)

p value

Laboratory variables

   

Functional MBL serum level, μg/mla

1.60 (0.04–7.00)

1.40 (0.04–7.60)

0.316

Functional MBL serum level <0.05 μg/ml

2/23 (9%)

11/80 (14%)

0.522

MBL-induced C4 deposition on mannan, percentagea

64.8 (3.4–400)

71.1 (1.1–400)

0.550

MBL-induced C4 deposition on mannan <10%

5/23 (22%)

16/80 (20%)

0.856

MBL pathway activity, percentagea

14.1 (0.1–111)

17.3 (0.1–119)

0.806

MBL pathway activity <10%

10/23 (44%)

34/80 (43%)

0.934

Clinical variables

   

Disease duration at follow-up, years

12.5 ± 7.4

5.1 ± 5.7

0.0001

Previous SLE glomerulonephritis

10/23 (44%)

10/80 (10%)

0.001

Treatment variables

Use <3 months before the first major infection

Previous use ever since lupus diagnosis

 

Oral corticosteroids

17/23 (74%)

41/80 (51%)

0.916

Intravenous methylprednisolone

5/23 (22%)

9/80 (11%)

0.204

Hydroxychloroquine

6/23 (26%)

70/80 (88%)

0.0001

Methotrexate

0/23 (0%)

9/80 (11%)

0.094

Azathioprine

8/23 (35%)

21/80 (26%)

0.424

Oral cyclophosphamide

1/23 (4%)

1/80 (1%)

0.373

Intravenous cyclophosphamide

4/23 (17%)

4/80 (5%)

0.065

  1. Except where indicated otherwise, values are presented as the mean ± standard deviation. aValues are presented as the median (range). MBL, mannose-binding lectin; SLE, systemic lupus erythematosus.